Taipei, Taiwan, Dec. 09, 2025 — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotech firm developing DNA methylation-based cancer detection and ophthalmologic innovations, today reported its successful involvement in the notable 9th Healthcare Expo Taiwan. The event took place from December 4-7, 2025, at TaipeiNEX 1. At Booth No. 4F, M1004, the Company displayed recent progress across three key areas: early cancer detection using DNA methylation and multi-biomarkers, next-generation precision diagnostics, and stem cell therapy & exosome platforms for ophthalmology. Attracting over 1,500 visitors and collecting 541 on-site surveys over four days, the expo acted as a vital conduit for YD Bio to link with important stakeholders, investigate worldwide market prospects, and solidify its standing as a healthcare innovator. It offered a unique venue to interact with top hospitals, technology leaders, and biotech pioneers from the region and internationally.
YD Bio Meets Industry Peers at Healthcare Expo Taiwan, Celebrates Successful Exhibition
The Company is of the view that its novel offerings, such as its sophisticated ophthalmologic solutions and the enhanced OkaiDx™ cancer detection platform, received considerable notice and favorable responses from participants. This positive reception highlights YD Bio’s pioneering status in cancer detection and treatment innovation and afforded key chances for networking and presenting its newest developments to a wide array of industry experts, prospective partners, and investors.
Throughout the exhibition, YD Bio also held fruitful talks with several international distributors based in China, Hong Kong, Indonesia, and Dubai. Each showed keen interest in working together to launch and grow the Company’s cancer detection and ophthalmology product lines in their local markets. These discussions mark a major step forward in YD Bio’s global commercialization plan, creating fresh avenues for OkaiDx™ and other cancer detection innovations in rapidly expanding areas.
The Company convened with many key opinion leaders, hospital administrators, and healthcare decision-makers from prominent Asian hospitals. Discussions centered on using EG BioMed US Inc.’s CLIA-certified and CAP-accredited U.S. laboratory as a global central hub for precise cancer testing services, as well as varying national regulatory and compliance needs. These dialogues forged significant opportunities to widen the clinical use of OkaiDx™ blood-based cancer detection tests in hospitals, medical centers, and health systems around the globe.
YD Bio believes the keen interest from global stakeholders points to the rising worldwide need for sophisticated early-detection and cancer treatment-monitoring tools. It also reaffirms the Company’s dedication to broadening international availability of precision cancer detection and preventive health solutions. Together, these exchanges emphasize the 9th Healthcare Expo Taiwan’s role as a crucial stage for boosting YD Bio’s global footprint and fortifying partnerships that enable the widespread clinical implementation of next-generation cancer detection technologies.
“We were delighted to take part in the 9th Healthcare Expo Taiwan, a key assembly for the international healthcare sector and a critically important occasion for our Company,” stated Dr. Ethan Shen, Chairman and CEO of the Company. “The expo gave us an outstanding chance to present our most recent progress to a varied global audience. We are focused on a practical journey from development to revenue in a large, demand-driven field, and we anticipate collaborating with partners and experts who align with our vision for a healthier future.”
YD Bio thanks all visitors to Booth No. 4F, M1004, for exploring potential collaborations and meeting the committed team driving healthcare innovation. The Company also appreciates the stimulating conversations and meaningful relationships formed during the event.
About YD Bio Limited
YD Bio Limited is a biotechnology company dedicated to progressing clinical trials, novel drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies that could revolutionize care for diseases with significant unmet medical needs. The Company aims to enhance patient results through scientific innovation and precision medicine. Beyond its R&D activities, YD Bio Limited is an established supplier of clinical trial pharmaceuticals and has moved into creating and distributing post-market auxiliary products. For further details, visit the Company’s website:
Forward-Looking Statements
This announcement contains forward-looking statements, which include, but are not limited to, YD Bio’s business strategy and prospects. These statements involve known and unknown risks and uncertainties and are founded on the Company’s present assumptions and forecasts regarding future events that may influence its financial position, operational results, business approach, and capital requirements. Investors can recognize these forward-looking statements by terms or expressions like “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or comparable phrases. YD Bio does not commit to publicly updating or revising any forward-looking statements to mirror subsequent events, situations, or expectation changes, except as mandated by law. While YD Bio considers the expectations in these forward-looking statements to be reasonable, it cannot guarantee their accuracy and warns investors that actual outcomes may vary significantly from projections. Investors are encouraged to examine other factors that might impact future performance in YD Bio’s registration statement and additional filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email:
WFS Investor Relations Inc.
Email:
Phone: +1 628 283 9214
